多替拉韦与利匹韦林联合西美瑞韦和索磷布韦在HIV/HCV合并肝硬化患者中的药代动力学
这项前瞻性观察研究纳入12例HIV/HCV合并肝硬化患者,评估多替拉韦和利匹韦林联合西美瑞韦和索磷布韦治疗时的血浆谷浓度。结果显示多替拉韦和利匹韦林谷浓度在基线至第4周无显著变化,所有患者完成抗HCV治疗并获得持续病毒学应答,提示该抗逆转录病毒方案在此类患者中适用。
要点
- 多替拉韦和利匹韦林谷浓度不受西美瑞韦联合索磷布韦影响。
- 所有患者完成抗HCV治疗并获得持续病毒学应答。
- 除两例外,其余患者HIV-RNA维持检测不到至治疗后24周。
核心结论
- 多替拉韦和利匹韦林谷浓度似乎不受西美瑞韦联合索磷布韦治疗影响,支持该抗逆转录病毒方案用于HIV/HCV合并肝硬化患者。
研究设计与样本
- 前瞻性观察研究,纳入12例接受多替拉韦联合利匹韦林抗逆转录病毒治疗并接受西美瑞韦联合索磷布韦(±利巴韦林)治疗的HIV/HCV合并肝硬化患者。
主要发现
- 利匹韦林和 multit 多替拉韦谷浓度几何均值(95%CI)在基线至第4周无变化(P=0.654和P=0.268),总体值分别为135(102-177)和1357(970-1897)ng/mL。
- GS-331007和西美瑞韦谷浓度总体几何均值(95%CI)分别为370(268-512)和2537(1569-4101)ng/mL,第2周与第4周间无显著变化(P=0.643和P=0.179)。
- 所有患者完成抗HCV治疗并获得持续病毒学应答;除两例外,其余患者HIV-RNA维持检测不到至治疗后第24周。
临床怎么用
- 在HIV/HCV合并肝硬化患者中,可考虑使用多替拉韦联合利匹韦林方案与西美瑞韦联合索磷布韦抗HCV治疗同时进行,无需调整抗逆转录病毒药物剂量。
局限性
- 样本量小(12例),且绝大多数为Child-Pugh A级,仅1例为B级,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the plasma trough concentrations ( C trough ) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed. PATIENTS AND METHODS: A prospective observational study in HIV/HCV-coinfected patients with liver cirrhosis on ART with dolutegravir plus rilpivirine and treated with simeprevir plus sofosbuvir (±ribavirin) was conducted. Dolutegravir, rilpivirine, GS-331007 (sofosbuvir metabolite) and simeprevir C trough were evaluated with a validated HPLC method at anti-HCV treatment baseline and weeks 2 and 4. Geometric means were calculated to summarize C trough values. RESULTS: Twelve patients were evaluated: 75% were males and the median (IQR) age was 53 (53-55) years. All patients were Child-Pugh stage A, except one who was stage B. The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL. The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively). All patients completed anti-HCV treatment, achieving sustained virological response. All but two patients maintained undetectable HIV-RNA up to post-treatment week 24. CONCLUSIONS: Dolutegravir and rilpivirine C trough appeared not to be affected by concomitant treatment with simeprevir plus sofosbuvir in these HIV/HCV-coinfected patients with liver cirrhosis, supporting the use of this antiretroviral regimen in this setting.
引用
- Merli M, Galli L, Marinaro L, et al. Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. J Antimicrob Chemother. 2017. PMID: 27999010. doi:10.1093/jac/dkw492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。